Discipline | Orthopedics |
---|---|
Language | English |
Publication details | |
History | 2002–2005 |
Publisher | Excerpta Medica Communications (Australia) |
Standard abbreviations | |
ISO 4 | Australas. J. Bone Jt. Med. |
Indexing | |
ISSN | 1447-5529 |
OCLC no. | 223430052 |
The Australasian Journal of Bone & Joint Medicine (originally titled the Australasian Journal of Musculoskeletal Medicine [1] ) was a periodical presented in the style of a scientific journal, published by Elsevier but established and funded by pharmaceutical company Merck. Publication began in 2002, [1] and the last issue appeared in 2005. [2] [3] According to The Scientist :
Merck paid an undisclosed sum to Elsevier to produce several volumes of [Australasian Journal of Bone and Joint Medicine], a publication that had the look of a peer-reviewed medical journal, but contained only reprinted or summarized articles—most of which presented data favorable to Merck products—that appeared to act solely as marketing tools with no disclosure of company sponsorship. [4] [5]
The publication was not included in the MEDLINE literature database and did not have its own website. [6]
In May 2009, Elsevier admitted that a series of similar industry sponsored publications had been produced, and that "high standards for disclosure were not followed in this instance". [3] In a formal statement, the CEO of Elsevier's Health Sciences Division, Michael Hansen, admitted that the practice was "unacceptable", and expressed regret for the publications. [7] Merck has denied claims that articles within it were ghost written by Merck and has stated that the articles were all reprinted from peer-reviewed medical journals. [8]
Several medical experts stated that their names were included in the Honorary Editorial Board of the Australasian Journal of Bone and Joint Medicine without their knowledge and consent. [9] [10]
There were six such "industry-sponsored" publications brought out by Elsevier without proper disclosure of their nature, and which had the superficial appearance of a legitimate independent journal. [11] [12] The six publications involved were:
Arthritis is a term often used to mean any disorder that affects joints. Symptoms generally include joint pain and stiffness. Other symptoms may include redness, warmth, swelling, and decreased range of motion of the affected joints. In some types of arthritis, other organs are also affected. Onset can be gradual or sudden.
Osteopathy, unlike osteopathic medicine, which is a branch of the medical profession in the United States, is a pseudoscientific system of alternative medicine that emphasizes physical manipulation of the body's muscle tissue and bones. In most countries, practitioners of osteopathy are not medically trained and are referred to as osteopaths.
Elsevier is a Dutch academic publishing company specializing in scientific, technical, and medical content. Its products include journals such as The Lancet, Cell, the ScienceDirect collection of electronic journals, Trends, the Current Opinion series, the online citation database Scopus, the SciVal tool for measuring research performance, the ClinicalKey search engine for clinicians, and the ClinicalPath evidence-based cancer care service. Elsevier's products and services include digital tools for data management, instruction, research analytics, and assessment. Elsevier is part of the RELX Group, known until 2015 as Reed Elsevier, a publicly traded company. According to RELX reports, in 2022 Elsevier published more than 600,000 articles annually in over 2,800 journals; as of 2018 its archives contained over 17 million documents and 40,000 e-books, with over one billion annual downloads.
Orthopedic surgery or orthopedics is the branch of surgery concerned with conditions involving the musculoskeletal system. Orthopedic surgeons use both surgical and nonsurgical means to treat musculoskeletal trauma, spine diseases, sports injuries, degenerative diseases, infections, tumors, and congenital disorders.
The New England Journal of Medicine (NEJM) is a weekly medical journal published by the Massachusetts Medical Society. Founded in 1812, the journal is among the most prestigious peer-reviewed medical journals. Its 2023 impact factor was 96.2, ranking it 2nd out of 168 journals in the category "Medicine, General & Internal".
Rofecoxib is a COX-2-selective nonsteroidal anti-inflammatory drug (NSAID). It was marketed by Merck & Co. to treat osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, acute pain conditions, migraine, and dysmenorrhea. Rofecoxib was approved in the US by the US Food and Drug Administration (FDA) in May 1999, and was marketed under the brand names Vioxx, Ceoxx, and Ceeoxx. Rofecoxib was available by prescription in both tablets and as an oral suspension.
The human musculoskeletal system is an organ system that gives humans the ability to move using their muscular and skeletal systems. The musculoskeletal system provides form, support, stability, and movement to the body.
Cyclooxygenase-2 inhibitors, also known as coxibs, are a type of nonsteroidal anti-inflammatory drug (NSAID) that directly target cyclooxygenase-2 (COX-2), an enzyme responsible for inflammation and pain. Targeting selectivity for COX-2 reduces the risk of peptic ulceration and is the main feature of celecoxib, rofecoxib, and other members of this drug class.
The Merck Manual of Diagnosis and Therapy, referred to as The Merck Manual, is the world's best-selling medical textbook, and the oldest continuously published English language medical textbook. First published in 1899, the current print edition of the book, the 20th Edition, was published in 2018. In 2014, Merck decided to move The Merck Manual to digital-only, online publication, available in both professional and consumer versions; this decision was reversed in 2017, with the publication of the 20th edition the following year. The Merck Manual of Diagnosis and Therapy is one of several medical textbooks, collectively known as The Merck Manuals, which are published by Merck Publishing, a subsidiary of the pharmaceutical company Merck Co., Inc. in the United States and Canada, and MSD in other countries in the world. Merck also formerly published The Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals.
Avascular necrosis (AVN), also called osteonecrosis or bone infarction, is death of bone tissue due to interruption of the blood supply. Early on, there may be no symptoms. Gradually joint pain may develop, which may limit the person's ability to move. Complications may include collapse of the bone or nearby joint surface.
The Medical Journal of Australia (MJA) is a peer-reviewed medical journal published 22 times a year. It is the official journal of the Australian Medical Association, published by Wiley on behalf of the Australasian Medical Publishing Company.
Eric Jeffrey Topol is an American cardiologist, scientist, and author. He is the founder and director of the Scripps Research Translational Institute, a professor of Molecular Medicine and Executive Vice-President at Scripps Research Institute, and a senior consultant at the Division of Cardiovascular Diseases at Scripps Clinic in La Jolla, California. He has published three bestseller books on the future of medicine: The Creative Destruction of Medicine (2010), The Patient Will See You Now (2015), and Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again (2019). He was commissioned by the UK from 2018–2019 to lead planning for the National Health Service's future workforce, integrating genomics, digital medicine, and artificial intelligence.
A seeding trial or marketing trial is a form of marketing, conducted in the name of research, designed to target product sampling towards selected consumers. In the marketing research field, seeding is the process of allocating marketing to specific customers, or groups of customers, in order to stimulate the internal dynamics of the market, and enhance the diffusion process. In medicine, seeding trials are clinical trials or research studies in which the primary objective is to introduce the concept of a particular medical intervention—such as a pharmaceutical drug or medical device—to physicians, rather than to test a scientific hypothesis.
The Drug Industry Documents Archive (DIDA) is a digital archive of pharmaceutical industry documents created and maintained by the University of California, San Francisco, Library and Center for Knowledge Management. DIDA is a part of the larger UCSF Industry Documents Library which includes the Truth Tobacco Industry Documents. The archive contains documents about pharmaceutical industry clinical trials, publication of study results, pricing, marketing, relations with physicians and drug company involvement in continuing medical education.
Scott S. Reuben is an American anesthesiologist who falsified data heralding the benefits of the Pfizer pain medication Celebrex while downplaying its negative side effects.
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of which it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.
Physical and Engineering Sciences in Medicine is a quarterly peer-reviewed medical journal covering research in medical physics and biomedical engineering. It is the official journal of the Australasian College of Physical Scientists and Engineers in Medicine and is recognized as an official journal of the International Organization for Medical Physics, Asia-Oceania Federation of Organizations for Medical Physics and the Biomedical College of Engineers Australia.
Edward Scolnick is a core investigator at the Broad Institute, the former founding director of the Stanley Center for Psychiatric Research at Broad Institute, and former head of research and development at Merck Research Laboratories.
John Michael Dwyer, is an Australian doctor, professor of medicine, and public health advocate. He was originally a Professor of Medicine and Paediatrics, then Head of the Department of Clinical Immunology at Yale University. Returning to Australia, he became Head of the Department of Medicine and the Clinical Dean at the University of New South Wales and Director of Medicine at Sydney's Prince of Wales Hospital, the University's major teaching hospital, for over twenty years. In retirement he is an Emeritus Professor of Medicine of the University. He founded the Australian Health Care Reform Alliance, and was the founding president of the Friends of Science in Medicine until 2019. He was appointed an Officer of the Order of Australia for his service to public health.
Conflicts of interest (COIs) often arise in academic publishing. Such conflicts may cause wrongdoing and make it more likely. Ethical standards in academic publishing exist to avoid and deal with conflicts of interest, and the field continues to develop new standards. Standards vary between journals and are unevenly applied. According to the International Committee of Medical Journal Editors, "[a]uthors have a responsibility to evaluate the integrity, history, practices and reputation of the journals to which they submit manuscripts".
It has recently come to my attention that from 2000 to 2005, our Australia office published a series of sponsored article compilation publications, on behalf of pharmaceutical clients, that were made to look like journals and lacked the proper disclosures. This was an unacceptable practice, and we regret that it took place.